Practical considerations in the use of lenalidomide therapy for myelodysplastic syndromes

Cancer Control

Volumn 13, Issue SUPPL., 2006, Pages 26-31

  Kurtin, Sandra ^a   Sokol, Lubomir ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; WARFARIN;

BIRTH DEFECT; CHROMOSOME 5Q; CHROMOSOME DELETION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CYTOPENIA; DEEP VEIN THROMBOSIS; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG MECHANISM; DRUG POTENTIATION; DRUG WITHDRAWAL; FATIGUE; FEVER; HUMAN; LUNG EMBOLISM; MONOTHERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PATIENT MONITORING; PRURITUS; RASH; REVIEW; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 33846426411     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480601304s05     Document Type: Review

References (9)

1. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352:549-557.
2. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355: 1456-1465.
3. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314-322.
4. Giagounidis AA, Germing U, Strupp C, et al. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Ann Hematol. 2005;84:569-571.
5. Weber D. Two phase III randomized, double-blind, placebo-controlled trials of lenalidomide-dexamethasone vs. dexamethasone for refractory and relapsed multiple myeloma. IMiDs: results of phase III studies in relapsed/refractory myeloma (Scientific Symposium), 2005 ASCO Annual Meeting [virtual meeting]. Available at http://www.asco.org/portal/site/ASCO/menuitem. 64cfbd0f85cb37b2eda2be0aee37a01d/?vgnextoid= 09f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=vm_search_results_view& selectedConfs=34&SearchFilter=Speaker&SearchTerm=Weber. Accessed on November 21, 2006.
6. Rajkumar SV, Blood E. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med. 2006;354:2079-2080.
7. Niesvizky R, Spencer A, Wang M, et al. Increased risk of thrombosis with lenalidomide in combination with dexamethasone and erythropoietin. Proc Annu Meet Am Soc Clin Oncol. 2006;24(18s):7506. Abstract.
8. FDA-approved package insert. Celgene Corp, Summit, NJ. 2006.
9. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology v4.2006. Myelodysplastic syndromes. 2006 National Comprehensive Cancer Network. Available at: http://www.nccn.org/professionals/physician_gls/ PDF/mds.pdf#search= 'national%20comprehensive%20cancer%20network%20practice%20guidelines%20 for%20MDS. Accessed November 21, 2006.